08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Melmed Holdings, Uluru sales and marketing update

On Dec. 18, 2013, Uluru and Altrazeal AG (formerly Altrazeal Trading Ltd.) added rights in India to an expanded 2012 deal granting Altrazeal AG exclusive rights to commercialize antimicrobial dressing Altrazeal in the EU, Australia,...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Melmed Holdings, Uluru sales and marketing update

Uluru and Altrazeal AG, an entity of Melmed, added rights in Latin America, the Commonwealth of Independent States (CIS) and markets not already licensed in Africa to a 2012 deal granting Altrazeal AG (formerly Altrazeal...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

Melmed Holdings, Uluru deal

Uluru signed a binding term sheet to grant Melmed worldwide rights to commercialize Uluru's OraDisc transmucosal erodible film delivery technology for oral and dental applications. Uluru will have a 25% stake in a subsidiary that...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

Melmed Holdings, Uluru sales and marketing update

Uluru said Melmed's Altrazeal Trading Ltd. subsidiary will launch Altrazeal in Austria this month. Uluru expects the product to launch in additional EU markets early next year. Melmed's subsidiary has exclusive rights to commercialize Altrazeal...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Melmed Holdings, Uluru sales and marketing update

Uluru finalized a deal granting Melmed's Altrazeal Trading Ltd. subsidiary exclusive rights to commercialize Altrazeal in the EU, Australia, New Zealand, North Africa and the Middle East. Uluru will receive $250,000 in licensing fees and...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Uluru, Melmed Holdings sales and marketing update

The companies added Australia and New Zealand to an October letter of intent granting an undisclosed Melmed subsidiary exclusive rights to commercialize Altrazeal in the EU. The deal has not been finalized. Uluru markets the...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Uluru, Melmed Holdings AG sales and marketing update

Uluru signed a letter of intent to grant a Melmed subsidiary exclusive rights to commercialize Altrazeal in the EU. Uluru markets the antimicrobial dressing incorporating the company's Nanoflex nanoparticle aggregate technology in the U.S. for...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

Altrazeal regulatory update

Uluru submitted an abbreviated 510(k) application to FDA to expand Altrazeal's label to include the management and mitigation of pain. Uluru already markets the antimicrobial dressing incorporating the company's Nanoflex nanoparticle aggregate technology in the...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Jiangxi Aiqilin Pharmaceuticals, Uluru deal

Uluru granted Jiangxi rights to commercialize Altrazeal in China, Hong Kong, Macau and Taiwan. Uluru already markets the antimicrobial dressing incorporating the company's Nanoflex nanoparticle aggregate technology in the U.S. for wound management. Uluru said...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

Altrazeal: Post-marketing study data

Data from a U.S. post-marketing study in 19 patients undergoing skin grafts showed that Altrazeal led to significantly lower pain scores vs. a marketed silver-containing carboxymethylcellulose dressing (p<0.0001). Altrazeal was also more comfortable and less...